GLM1
MCID: GLM040
MIFTS: 62

Glioma Susceptibility 1 (GLM1)

Categories: Cancer diseases, Genetic diseases, Neuronal diseases

Aliases & Classifications for Glioma Susceptibility 1

MalaCards integrated aliases for Glioma Susceptibility 1:

Name: Glioma Susceptibility 1 57 29 6
Glioblastoma Multiforme 75 73
Glioblastoma, Somatic 57 13
Oligodendroglioma 75 73
Astrocytoma 75 73
Glioma 75 73
Glm1 57 75
Well Differentiated Oligodendroglioma 73
Glioma, Susceptibility to, Somatic 57
Glioma, Susceptibility, Type 1 40
Familial Glioma of Brain 75
Glioma Somatic 57
Glioblastoma 73
Glioma 1 75
Gbm 75
Glm 75

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant
somatic mutation

Miscellaneous:
gliomas may occur in association with other hereditary tumor syndromes (see )


HPO:

32
glioma susceptibility 1:
Inheritance somatic mutation autosomal dominant inheritance


Classifications:



Summaries for Glioma Susceptibility 1

OMIM : 57 Gliomas are central nervous system neoplasms derived from glial cells and comprise astrocytomas, glioblastoma multiforme, oligodendrogliomas, ependymomas, and subependymomas. Glial cells can show various degrees of differentiation even within the same tumor (summary by Kyritsis et al., 2010). Ependymomas are rare glial tumors of the brain and spinal cord (Yokota et al., 2003). Subependymomas are unusual tumors believed to arise from the bipotential subependymal cell, which normally differentiates into either ependymal cells or astrocytes. They were characterized as a distinct entity by Scheinker (1945). They tend to be slow-growing, noninvasive, and located in the ventricular system, septum pellucidum, cerebral aqueduct, or proximal spinal cord (summary by Ryken et al., 1994). Gliomas are known to occur in association with several other well-defined hereditary tumor syndromes such as mismatch repair cancer syndrome (276300), melanoma-astrocytoma syndrome (155755), neurofibromatosis-1 (NF1; 162200) and NF2 (101000), and tuberous sclerosis (TSC1; 191100). Familial clustering of gliomas may occur in the absence of these tumor syndromes, however. (137800)

MalaCards based summary : Glioma Susceptibility 1, also known as glioblastoma multiforme, is related to glioblastoma multiforme and cerebellar astrocytoma, and has symptoms including seizures and headache. An important gene associated with Glioma Susceptibility 1 is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Factors involved in megakaryocyte development and platelet production and UVA-Induced MAPK Signaling. The drugs Afinitor and Gliadel Wafer have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and t cells, and related phenotypes are astrocytoma and ependymoma

UniProtKB/Swiss-Prot : 75 Glioma: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes.

Related Diseases for Glioma Susceptibility 1

Diseases in the Glioma Susceptibility 1 family:

Glioma Susceptibility 4 Glioma Susceptibility 2
Glioma Susceptibility 3 Glioma Susceptibility 5
Glioma Susceptibility 6 Glioma Susceptibility 7
Glioma Susceptibility 8 Glioma Susceptibility 9

Diseases related to Glioma Susceptibility 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 765)
# Related Disease Score Top Affiliating Genes
1 glioblastoma multiforme 33.9 ERBB2 GFAP IDH1 PPARG TP53
2 cerebellar astrocytoma 33.6 TP53 IDH1
3 chordoid glioma 33.5 TP53 GFAP
4 childhood oligodendroglioma 33.5 IDH1 GFAP
5 adult oligodendroglioma 33.4 IDH2 IDH1
6 brain glioma 33.4 TP53 IDH1 GFAP
7 gemistocytic astrocytoma 33.2 IDH2 GFAP
8 pilocytic astrocytoma of cerebellum 33.2 IDH2 IDH1
9 fibrillary astrocytoma 33.1 TP53 IDH2 IDH1 H3F3A GFAP
10 protoplasmic astrocytoma 33.1 GFAP IDH2 TP53
11 spinal cord astrocytoma 33.0 TP53 IDH1 H3F3A GFAP
12 brain stem glioma 32.8 TP53 IDH2 IDH1 HIST1H3A H3F3A
13 oligoastrocytoma 32.7 IDH2 GFAP
14 benign glioma 32.7 TP53 PPARG H3F3A GFAP
15 giant cell glioblastoma 32.2 PPARG TP53 IDH1 GFAP
16 malignant ependymoma 31.6 TP53 GFAP
17 adult astrocytic tumour 31.1 IDH2 IDH1 H3F3A
18 grade iii astrocytoma 30.8 TP53 IDH2 GFAP
19 gliosarcoma 30.4 GFAP TP53 PPARG IDH1
20 pilocytic astrocytoma 30.3 IDH1 GFAP
21 extraventricular neurocytoma 30.3 IDH1 GFAP
22 pleomorphic xanthoastrocytoma 30.3 TP53 IDH1 GFAP
23 ganglioglioma 30.2 TP53 H3F3A GFAP
24 cerebral neuroblastoma 30.1 TP53 GFAP
25 gliomatosis cerebri 30.1 TP53 IDH1 GFAP
26 gliofibroma 30.0 TP53 GFAP
27 choroid plexus cancer 30.0 GFAP TP53
28 brain cancer 30.0 TP53 IDH2 IDH1 GFAP
29 medulloblastoma 30.0 TP53 IDH1 GFAP ERBB2
30 dysembryoplastic neuroepithelial tumor 30.0 IDH1 GFAP
31 juvenile pilocytic astrocytoma 30.0 TP53 GFAP
32 optic nerve glioma 29.9 GFAP TP53
33 cerebellar liponeurocytoma 29.8 TP53 GFAP
34 mixed glioma 29.8 TP53 IDH1 GFAP
35 angiocentric glioma 29.8 IDH1 GFAP
36 anaplastic oligodendroglioma 29.8 IDH2 GFAP
37 enchondromatosis, multiple, ollier type 29.7 IDH1 IDH2
38 glioma 29.6 TP53 PPARG IDH2 IDH1 HIST1H3A H3F3A
39 cystic teratoma 29.6 GFAP TP53
40 myeloma, multiple 29.6 TP53 IDH2 IDH1
41 pleomorphic adenoma 29.5 TP53 GFAP ERBB2
42 diffuse intrinsic pontine glioma 29.5 HIST1H3A H3F3A
43 nervous system cancer 29.4 TP53 IDH1 GFAP
44 atypical teratoid rhabdoid tumor 29.4 GFAP TP53
45 oligodendroglioma 29.4 TP53 IDH2 IDH1 GFAP
46 2-hydroxyglutaric aciduria 29.3 IDH2 IDH1
47 glioblastoma 29.1 TP53 PPARG IDH2 IDH1 H3F3A ERBB2
48 central nervous system cancer 28.7 TP53 IDH2 IDH1 H3F3A GFAP
49 brain glioblastoma multiforme 12.6
50 subependymal giant cell astrocytoma 12.5

Graphical network of the top 20 diseases related to Glioma Susceptibility 1:



Diseases related to Glioma Susceptibility 1

Symptoms & Phenotypes for Glioma Susceptibility 1

Symptoms via clinical synopsis from OMIM:

57
Neoplasia:
astrocytomas
glioblastoma multiforme
oligodendrogliomas
ependymomas
subependymomas


Clinical features from OMIM:

137800

Human phenotypes related to Glioma Susceptibility 1:

32
# Description HPO Frequency HPO Source Accession
1 astrocytoma 32 HP:0009592
2 ependymoma 32 HP:0002888
3 glioblastoma multiforme 32 HP:0012174

UMLS symptoms related to Glioma Susceptibility 1:


seizures, headache

Drugs & Therapeutics for Glioma Susceptibility 1

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Afinitor 18 49 EVEROLIMUS Novartis March 2009
2
Gliadel Wafer 18 49 CARMUSTINE Rhone-Poulenc Rorer, Guilford Pharmaceuticals February 1997
3
Temodar 18 49 TEMOZOLOMIDE Schering-Plough August 1999

Search Clinical Trials , NIH Clinical Center for Glioma Susceptibility 1

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Glioma Susceptibility 1

Genetic tests related to Glioma Susceptibility 1:

# Genetic test Affiliating Genes
1 Glioma Susceptibility 1 29 ERBB2 IDH1 TP53

Anatomical Context for Glioma Susceptibility 1

MalaCards organs/tissues related to Glioma Susceptibility 1:

41
Brain, Spinal Cord, T Cells, Testes, Endothelial, Prostate, Bone

Publications for Glioma Susceptibility 1

Articles related to Glioma Susceptibility 1:

(show top 50) (show all 1537)
# Title Authors Year
1
Analyses of temporal and spatial patterns of glioblastoma multiforme and other brain cancer subtypes in relation to mobile phones using synthetic counterfactuals. ( 30384227 )
2019
2
MicroRNA‑876‑5p inhibits the progression of glioblastoma multiforme by directly targeting Forkhead box M1. ( 30365126 )
2019
3
Glycogen synthase kinase-3 inhibition in glioblastoma multiforme cells induces apoptosis, cell cycle arrest and changing biomolecular structure. ( 30388586 )
2019
4
EPH Profiling of BTIC Populations in Glioblastoma Multiforme Using CyTOF. ( 30324522 )
2019
5
Glioblastoma multiforme subterfuge as acute cerebral hemorrhage: A case report and literature review. ( 29844891 )
2018
6
Evaluation of the relationship of erythrocyte membrane Na+/K+-ATPase enzyme activity and tumor response to chemoradiotherapy in patients diagnosed with locally advanced nonsmall cell lung cancer and glioblastoma multiforme. ( 29970705 )
2018
7
Benzyl isothiocyanate inhibits human brain glioblastoma multiforme GBM 8401 cell xenograft tumor in nude mice in vivo. ( 29972272 )
2018
8
High-dose fotemustine in temozolomide-pretreated glioblastoma multiforme patients: A phase I/II trial. ( 29979390 )
2018
9
Venous thromboembolic complications with and without intermittent intraoperative and postoperative pneumatic compression in patients with glioblastoma multiforme using intraoperative magnetic resonance imaging. A retrospective study. ( 29859696 )
2018
10
Inhibition of GLO1 in Glioblastoma Multiforme Increases DNA-AGEs, Stimulates RAGE Expression, and Inhibits Brain Tumor Growth in Orthotopic Mouse Models. ( 29385725 )
2018
11
Prognostic stratification of adult primary glioblastoma multiforme patients based on their tumor gene amplification profiles. ( 29963263 )
2018
12
microRNAa89574 inhibits cell proliferation and invasion in glioblastoma multiforme by directly targeting zinc finger Ea89boxa89binding homeobox 1. ( 29901177 )
2018
13
Specifically Targeted Electromagnetic Fields Arrest Proliferation of Glioblastoma Multiforme U-87 Cells in Culture. ( 29848672 )
2018
14
A case of subgaleal metastasis from glioblastoma multiforme. ( 29898273 )
2018
15
Does radiation therapy increase gadolinium accumulation in the brain?: Quantitative analysis of T1 shortening using R1 relaxometry in glioblastoma multiforme patients. ( 29444157 )
2018
16
Mutant cytoskeletal and ECM peptides sensitive to the ST14 protease are associated with a worse outcome for glioblastoma multiforme. ( 29953855 )
2018
17
Platelet activation parameters and platelet-leucocyte-conjugate formation in glioblastoma multiforme patients. ( 29899827 )
2018
18
Comparative proteomics as a tool for identifying specific alterations within interferon response pathways in human glioblastoma multiforme cells. ( 29416731 )
2018
19
Hyaluronic Acid-Modified Micelles Encapsulating Gem-C<sub>12</sub>and HNK for Glioblastoma Multiforme Chemotherapy. ( 29397747 )
2018
20
Early candidate biomarkers found from urine of glioblastoma multiforme rat before changes in MRI. ( 29372508 )
2018
21
Enhanced radiosensitization of human glioblastoma multiforme cells with phosphorylated peptides derived from Gli2. ( 29880393 )
2018
22
Semantic imaging features predict disease progression and survival in glioblastoma multiforme patients. ( 29442128 )
2018
23
Cell biology of glioblastoma multiforme: from basic science to diagnosis and treatment. ( 29387965 )
2018
24
A Rare Case of Concurrent Herpes Simplex Encephalitis and Glioblastoma Multiforme. ( 29492128 )
2018
25
Long-term follow-up results of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastoma multiforme patients. The importance of MRI information in survival: Single-center experience. ( 29889468 )
2018
26
Glioblastoma multiforme: another potential application for<sup>68</sup>Ga-PSMA PET/CT as a guide for targeted therapy. ( 29387926 )
2018
27
Reactive Astrocytes in Glioblastoma Multiforme. ( 29363044 )
2018
28
Longevity-Related Gene Transcriptomic Signature in Glioblastoma Multiforme. ( 29849920 )
2018
29
ATM and p53 combined analysis predicts survival in glioblastoma multiforme patients: a clinicopathologic study. ( 29369420 )
2018
30
Glioblastoma Multiforme: Fewer Tumor Copy Number Segments of the <i>SGK1</i> Gene Are Associated with Poorer Survival. ( 29976632 )
2018
31
Galectin-1 is a poor prognostic factor in patients with glioblastoma multiforme after radiotherapy. ( 29378529 )
2018
32
High expression of a novel splicing variant of VEGF, L-VEGF144 in glioblastoma multiforme is associated with a poorer prognosis in bevacizumab treatment. ( 29909500 )
2018
33
Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme. ( 29910795 )
2018
34
CircSMARCA5 Inhibits Migration of Glioblastoma Multiforme Cells by Regulating a Molecular Axis Involving Splicing Factors SRSF1/SRSF3/PTB. ( 29415469 )
2018
35
A Non-randomized Controlled Trial of EMDR on Affective Symptoms in Patients With Glioblastoma Multiforme. ( 29892240 )
2018
36
Cucurbitacin B induces inhibitory effects via CIP2A/PP2A/Akt pathway in glioblastoma multiforme. ( 29393542 )
2018
37
Management of Elderly patients with Glioblastoma - Multiforme. ( 29376741 )
2018
38
Cancer stem cells from peritumoral tissue of glioblastoma multiforme: the possible missing link between tumor development and progression. ( 29963265 )
2018
39
Carbonic anhydrase IX is a prognostic biomarker in glioblastoma multiforme. ( 29952031 )
2018
40
New Tetrahydroisoquinoline Derivatives Overcome Pgp Activity in Brain-Blood Barrier and Glioblastoma Multiforme in Vitro. ( 29890725 )
2018
41
Development of an exercise intervention as part of rehabilitation in a glioblastoma multiforme survivor during irradiation treatment: a case report. ( 29382243 )
2018
42
Stereotactic Radiosurgery in the Multimodality Management of Residual or Recurrent Glioblastoma Multiforme. ( 29393176 )
2018
43
Tetrandrine inhibits human brain glioblastoma multiforme GBM 8401 cancer cell migration and invasion in vitro. ( 30549224 )
2018
44
Synchronous glioblastoma multiforme and chondrosarcoma: A case report and review of the literature. ( 29628192 )
2018
45
New extracellular factors in glioblastoma multiforme development: neurotensin, growth differentiation factor-15, sphingosine-1-phosphate and cytomegalovirus infection. ( 29467963 )
2018
46
AGAP2-AS1 serves as an oncogenic lncRNA and prognostic biomarker in glioblastoma multiforme. ( 30525219 )
2018
47
Piezoelectric barium titanate nanostimulators for the treatment of glioblastoma multiforme. ( 30537658 )
2018
48
Oncolytic myxoma virus synergizes with standard of care for treatment of glioblastoma multiforme. ( 30538967 )
2018
49
Effects of Reduced Graphene Oxides on Apoptosis and Cell Cycle of Glioblastoma Multiforme. ( 30544611 )
2018
50
CD133 Expression in Glioblastoma Multiforme: A Literature Review. ( 30555755 )
2018

Variations for Glioma Susceptibility 1

UniProtKB/Swiss-Prot genetic disease variations for Glioma Susceptibility 1:

75
# Symbol AA change Variation ID SNP ID
1 H3F3A p.Lys28Met VAR_079021 rs105751990
2 H3F3A p.Gly35Arg VAR_079022
3 H3F3A p.Gly35Val VAR_079023
4 HIST1H3A p.Lys28Met VAR_079018 rs105751990
5 IDH2 p.Pro158Leu VAR_073181
6 IDH2 p.Pro162Ser VAR_073182
7 IDH2 p.Arg172Gly VAR_073183 rs105751990
8 IDH2 p.Arg172Lys VAR_073184 rs121913503
9 IDH2 p.Arg172Met VAR_073185

ClinVar genetic disease variations for Glioma Susceptibility 1:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 PPARG NM_015869.4(PPARG): c.1431C> T (p.His477=) single nucleotide variant Likely benign rs3856806 GRCh37 Chromosome 3, 12475557: 12475557
2 PPARG NM_015869.4(PPARG): c.1431C> T (p.His477=) single nucleotide variant Likely benign rs3856806 GRCh38 Chromosome 3, 12434058: 12434058
3 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
4 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh38 Chromosome 17, 7673802: 7673802
5 ERBB2 NM_001005862.2(ERBB2): c.2650G> A (p.Glu884Lys) single nucleotide variant Pathogenic rs28933368 GRCh37 Chromosome 17, 37881974: 37881974
6 ERBB2 NM_001005862.2(ERBB2): c.2650G> A (p.Glu884Lys) single nucleotide variant Pathogenic rs28933368 GRCh38 Chromosome 17, 39725721: 39725721
7 TP53 NM_000546.5(TP53): c.542G> T (p.Arg181Leu) single nucleotide variant Uncertain significance rs397514495 GRCh37 Chromosome 17, 7578388: 7578388
8 TP53 NM_000546.5(TP53): c.542G> T (p.Arg181Leu) single nucleotide variant Uncertain significance rs397514495 GRCh38 Chromosome 17, 7675070: 7675070

Cosmic variations for Glioma Susceptibility 1:

9 (show top 50) (show all 7048)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM989 SMARCB1 central nervous system,brain,glioma,ependymoma Grade III-IV c.1130G>A p.R377H 22:23834152-23834152 16
2 COSM6289136 SMARCA4 central nervous system,brain,glioma,ependymoma Grade III-IV c.2143G>A p.D715N 19:11010400-11010400 16
3 COSM6958006 RB1 central nervous system,brain,glioma,ependymoma Grade III-IV c.380+2T>C p.? 13:48342716-48342716 16
4 COSM4749148 PTPRS central nervous system,brain,glioma,ependymoma Grade III-IV c.2600G>A p.R867H 19:5223192-5223192 16
5 COSM6968454 PIK3R3 central nervous system,brain,glioma,ependymoma Grade III-IV c.1320C>A p.H440Q 1:46043739-46043739 16
6 COSM6973319 PIK3C3 central nervous system,brain,glioma,ependymoma Grade III-IV c.929A>T p.Y310F 18:41996675-41996675 16
7 COSM6968460 KMT2C central nervous system,brain,glioma,ependymoma Grade III-IV c.14594G>A p.G4865E 7:152138845-152138845 16
8 COSM3662778 KMT2C central nervous system,brain,glioma,ependymoma Grade III-IV c.2491A>G p.T831A 7:152247943-152247943 16
9 COSM6968457 FLT4 central nervous system,brain,glioma,ependymoma Grade III-IV c.2105C>A p.A702D 5:180621168-180621168 16
10 COSM6942397 FH central nervous system,brain,glioma,ependymoma Grade III-IV c.258A>C p.E86D 1:241517191-241517191 16
11 COSM22965 FBXW7 central nervous system,brain,glioma,ependymoma Grade III-IV c.1394G>A p.R465H 4:152328232-152328232 16
12 COSM4607064 CDC73 central nervous system,brain,glioma,ependymoma Grade III-IV c.929A>G p.D310G 1:193152401-193152401 16
13 COSM1162555 APC central nervous system,brain,glioma,ependymoma Grade III-IV c.3007G>A p.D1003N 5:112838601-112838601 16
14 COSM1149856 central nervous system,brain,glioma,ependymoma Grade III-IV c.1040G>A p.R347H 4:152328232-152328232 16
15 COSM4749147 central nervous system,brain,glioma,ependymoma Grade III-IV c.2603G>A p.R868H 19:5223192-5223192 16
16 COSM117310 central nervous system,brain,glioma,ependymoma Grade III-IV c.1394G>A p.R465H 4:152328232-152328232 16
17 COSM6914403 central nervous system,brain,glioma,ependymoma Grade III-IV c.2588G>A p.R863H 19:5223192-5223192 16
18 COSM6968458 central nervous system,brain,glioma,ependymoma Grade III-IV c.1535C>A p.A512D 5:180621168-180621168 16
19 COSM6958005 central nervous system,brain,glioma,ependymoma Grade III-IV c.380+2T>C p.? 13:48342716-48342716 16
20 COSM3662777 central nervous system,brain,glioma,ependymoma Grade III-IV c.2491A>G p.T831A 7:152247943-152247943 16
21 COSM6968456 central nervous system,brain,glioma,ependymoma Grade III-IV c.2105C>A p.A702D 5:180621168-180621168 16
22 COSM6289135 central nervous system,brain,glioma,ependymoma Grade III-IV c.2143G>A p.D715N 19:11010400-11010400 16
23 COSM1578803 central nervous system,brain,glioma,ependymoma Grade III-IV c.1157G>A p.R386H 22:23834152-23834152 16
24 COSM6968459 central nervous system,brain,glioma,ependymoma Grade III-IV c.14765G>A p.G4922E 7:152138845-152138845 16
25 COSM6968455 central nervous system,brain,glioma,ependymoma Grade III-IV c.1458C>A p.H486Q 1:46043739-46043739 16
26 COSM40802 ZW10 central nervous system,brain,glioma,astrocytoma Grade III c.2140C>T p.P714S 11:113736699-113736699 14
27 COSM40801 ZSWIM4 central nervous system,brain,glioma,astrocytoma Grade III c.266C>T p.P89L 19:13799832-13799832 14
28 COSM6932117 ZRSR2 central nervous system,brain,glioma,astrocytoma Grade III c.271G>A p.E91K 23:15803755-15803755 14
29 COSM6948317 ZRSR2 central nervous system,brain,glioma,astrocytoma Grade III c.340C>T p.Q114* 23:15804138-15804138 14
30 COSM6959574 ZRSR2 central nervous system,brain,glioma,astrocytoma Grade III c.260G>A p.R87K 23:15803744-15803744 14
31 COSM6932118 ZRSR2 central nervous system,brain,glioma,astrocytoma Grade III c.961C>T p.P321S 23:15822754-15822754 14
32 COSM6973162 ZRSR2 central nervous system,brain,glioma,oligodendroglioma Grade III c.220G>A p.E74K 23:15803704-15803704 14
33 COSM39611 ZPLD1 central nervous system,brain,glioma,astrocytoma Grade III c.393A>T p.G131G 3:102456210-102456210 14
34 COSM40237 ZNF687 central nervous system,brain,glioma,astrocytoma Grade III c.3651C>T p.T1217T 1:151291146-151291146 14
35 COSM39318 ZNF687 central nervous system,brain,glioma,astrocytoma Grade III c.2044T>A p.C682S 1:151288335-151288335 14
36 COSM39317 ZNF687 central nervous system,brain,glioma,astrocytoma Grade III c.2043G>C p.Q681H 1:151288334-151288334 14
37 COSM39149 ZNF507 central nervous system,brain,glioma,astrocytoma Grade III c.1517G>C p.R506T 19:32354347-32354347 14
38 COSM40794 ZNF473 central nervous system,brain,glioma,astrocytoma Grade III c.42C>T p.D14D 19:50039193-50039193 14
39 COSM39217 ZMYND8 central nervous system,brain,glioma,astrocytoma Grade III c.2162T>G p.V721G 20:47246130-47246130 14
40 COSM40504 ZMYND8 central nervous system,brain,glioma,astrocytoma Grade III c.2176G>A p.D726N 20:47246116-47246116 14
41 COSM39507 ZMAT4 central nervous system,brain,glioma,astrocytoma Grade III c.76G>A p.E26K 8:40825601-40825601 14
42 COSM39445 ZIC1 central nervous system,brain,glioma,NS c.57G>A p.A19A 3:147410169-147410169 14
43 COSM6976869 ZFHX3 central nervous system,brain,glioma,astrocytoma Grade III c.4279G>A p.A1427T 16:72798403-72798403 14
44 COSM6929045 ZFHX3 central nervous system,brain,glioma,astrocytoma Grade III c.3607G>T p.E1203* 16:72811961-72811961 14
45 COSM6950242 ZFHX3 central nervous system,brain,glioma,oligodendroglioma Grade III c.8300G>A p.G2767E 16:72794382-72794382 14
46 COSM6959528 ZFHX3 central nervous system,brain,glioma,astrocytoma Grade III c.145C>T p.P49S 16:72960001-72960001 14
47 COSM5385367 ZFHX3 central nervous system,brain,glioma,astrocytoma Grade III c.934G>A p.D312N 16:72959212-72959212 14
48 COSM6980194 ZFHX3 central nervous system,brain,glioma,oligodendroglioma Grade III c.6025T>C p.Y2009H 16:72796657-72796657 14
49 COSM5981027 ZFHX3 central nervous system,brain,glioma,astrocytoma Grade III c.8647A>G p.M2883V 16:72794035-72794035 14
50 COSM3888943 ZFHX3 central nervous system,brain,glioma,astrocytoma Grade III c.8198G>A p.R2733H 16:72794484-72794484 14

Expression for Glioma Susceptibility 1

Search GEO for disease gene expression data for Glioma Susceptibility 1.

Pathways for Glioma Susceptibility 1

GO Terms for Glioma Susceptibility 1

Cellular components related to Glioma Susceptibility 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nuclear nucleosome GO:0000788 8.96 H3F3A HIST1H3A
2 protein-containing complex GO:0032991 8.92 H3F3A HIST1H3A PPARG TP53

Biological processes related to Glioma Susceptibility 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chromatin silencing at rDNA GO:0000183 9.43 H3F3A HIST1H3A
2 tricarboxylic acid cycle GO:0006099 9.4 IDH1 IDH2
3 telomere organization GO:0032200 9.37 H3F3A HIST1H3A
4 2-oxoglutarate metabolic process GO:0006103 9.32 IDH1 IDH2
5 negative regulation of telomerase activity GO:0051974 9.26 PPARG TP53
6 NADP metabolic process GO:0006739 9.16 IDH1 IDH2
7 isocitrate metabolic process GO:0006102 8.96 IDH1 IDH2
8 glyoxylate cycle GO:0006097 8.62 IDH1 IDH2

Molecular functions related to Glioma Susceptibility 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.72 ERBB2 GFAP IDH1 PPARG TP53
2 protein heterodimerization activity GO:0046982 9.55 ERBB2 H3F3A HIST1H3A PPARG TP53
3 protein phosphatase binding GO:0019903 9.43 ERBB2 PPARG TP53
4 NAD binding GO:0051287 9.4 IDH1 IDH2
5 oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor GO:0016616 9.37 IDH1 IDH2
6 isocitrate dehydrogenase (NADP+) activity GO:0004450 8.96 IDH1 IDH2
7 isocitrate dehydrogenase activity GO:0004448 8.62 IDH1 IDH2

Sources for Glioma Susceptibility 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....